Clinical Trials Directory

A Feasibility Study Evaluating Haploidentical Allogeneic Transplantation Using the CliniMACS System in Patients With Advanced Hematologic Malignancies

To assess the proportion of patients with donor neutrophil engraftment within 30 days of allogeneic transplant. To assess the incidence of acute GvHD during the first 100 days after transplantation.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • device : CliniMACS System

Phase: Phase 2


Ages Eligible For Study:

18 Years - 50 Years

External Links

Footer Links: